Is Amnestic Mild Cognitive Impairment a Neuro-Immune Condition?

doi:10.21203/rs.3.rs-4714669/v1

Download PDF

Article

Is Amnestic Mild Cognitive Impairment a Neuro-Immune Condition?

https://doi.org/10.21203/rs.3.rs-4714669/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Objectives

The pathophysiology of amnestic Mild Cognitive Impairment (aMCI) is largely unknown, although some papers found signs of immune activation. To assess the cytokine network in aMCI after excluding patients with major depression (MDD) and to examine the immune profiles of quantitative aMCI (qMCI) and distress symptoms of old age (DSOA) scores.

Design:

A case-control study.

Setting:

Department of Psychiatry of a University Hospital, Bangkok, Thailand.

Participants

: 61 Thai aMCI participants and 60 healthy old adults (both without MDD).

Measurements

: The Bio-Plex Pro human cytokine 27-plex test kit was used to assay cytokines/chemokines/growth factors in fasting plasma samples.

Results

aMCI is characterized by significant general immunosuppression, and reductions in T helper 1 (Th)1 and T cell growth profiles, the immune-inflammatory responses system, interleukin (IL)1β, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1. These 7 cytokines/chemokines exhibit neuroprotective effects at physiologic concentrations. In multivariate analyses, three neurotoxic chemokines, CCL11, CCL5, and CXCL8, emerged as significant predictors of aMCI. Logistic regression showed that aMCI was best predicted by combining IL7, IL1β, MCP-1, years of education (all inversely associated) and CCL5 (positively associated). We found that 38.2% of the variance in the qMCI score was explained by IL7, IL1β, MCP-1, IL13, years of education (inversely associated) and CCL5 (positively associated). The DSOA was not associated with any immune data.

Discussion

A dysbalance between lowered levels of neuroprotective cytokines and chemokines, and relative increases in neurotoxic chemokines are key factors in aMCI. Future MCI research should always control for the confounding effects of affective symptoms.

Biological sciences/Immunology

Health sciences/Medical research/Biomarkers

neuroimmune

inflammation

depression

neurocognition

immune biomarkers

chemokines

Among older adults, the occurrence of mild cognitive impairment (MCI) is quite significant, affecting approximately 10–15% of individuals aged 65 and above [1]. Amnestic MCI (aMCI) is characterized by mild deficits in various cognitive domains, such as episodic memory, executive functions, visuospatial skills, processing speed, cognitive flexibility, and problem-solving ability [2–4]. Nevertheless, individuals with aMCI generally demonstrate intact abilities related to everyday tasks, as observed in various studies [5–7]. aMCI is a cognitive stage that falls between the normal aging process and the onset of dementia [1]. It is worth noting that the annual conversion rate from aMCI to Alzheimer's disease (AD) is approximately 16.5%. Nevertheless, a small percentage of patients with aMCI (8%) exhibit a remission from this condition, as noted by Petersen et al. [8].

The evaluation of aMCI poses two significant challenges. At first, it is uncertain if the findings regarding the neurocognitive aspects of MCI in older individuals are still applicable when patients with major depression (MDD) are excluded. Depressive symptoms can significantly affect the neurocognitive aspects of MCI, which poses challenges in interpreting assessments conducted in MCI studies that did not exclude patients with MDD [3]. In addition, it has been argued that the existing diagnostic criteria for aMCI are excessively permissive, as suggested by Maes, Tangwongchai [9]. The ongoing debate revolves around the distinctiveness of aMCI as a phenotype and the possibility that some individuals classified as aMCI could actually be part of the normal control sample [4, 9]. In a study conducted by Tran-Chi et al. [3], it was discovered that older individuals without MDD exhibited two distinct symptom dimensions. The first dimension, distress symptoms of old age (DSOA), encompasses emotions such as depression, anxiety, tension, and neuroticism. This aspect demonstrates a significant correlation with negative life events and adverse childhood experiences [3]. The second dimension involves a quantitative score of aMCI severity (labeled as qMCI), which provides an indication of the extent of objective cognitive decline. The score is calculated by taking into account the first principal component of the Montreal Cognitive Assessment (MoCA) and the Mini Mental State Examination (MMSE) scores, as well as the modified Clinical Dementia Rating (CDR) [3]. In addition, through cluster analysis, it has been determined that the diagnostic criteria for aMCI proposed by Petersen [10] are excessively broad. This is due to the fact that the aMCI group consists of individuals with subjective indicators of cognitive impairment, specifically subjects with DSOA after removing those with MDD [3].

Research suggests that the activation of the immune system in the peripheral blood may contribute to neuroinflammation, thereby contributing to neurocognitive deficits and Alzheimer’s disease [11, 12]. Peripheral inflammatory responses and heightened microglia-associated signaling are now considered crucial phenomena in Alzheimer's disease, as highlighted by Kinney et al. [13]. Additionally, some studies have indicated that MCI is linked to elevated levels of immune compounds such as interleukin-6 (IL-6) and C-reactive protein (CRP) in serum or cerebro-spinal fluid (CSF) [14, 15]. Interestingly, increased IL-6 and tumor necrosis factor (TNF)-α, have been linked to a higher likelihood of MCI progressing to Alzheimer’s disease [16]. A meta-analysis conducted by Shen et al. [17] found that individuals with MCI have elevated levels of IL-6, MCP-1, and soluble TNF receptor 2 (sTNFR2) in their serum, in comparison to the control group. Nevertheless, another meta-analysis, conducted by Saleem et al. [18], found no significant alterations in immune variables in individuals with MCI. This includes acute phase reactants, immunoglobulins, cytokines, chemokines, and adhesion molecules.

Nevertheless, there has been a lack of research investigating comprehensive cytokine/chemokine profiles in individuals with aMCI after excluding those with MDD. Additionally, there is a dearth of research exploring the connections between the quantitative qMCI and DSOA scores and the comprehensive immune profiles in those MCI subjects without MDD. It should be stressed that MDD is currently recognized as a neuro-immune disorder, marked by elevated levels of pro-inflammatory cytokines, acute phase proteins, and complement factors [19–21]. Moreover, the heightened neurotoxicity resulting from the impact of pro-inflammatory cytokines/chemokines on neurons is linked to MDD as well as the intensity of depression and anxiety [21, 22].

Thus, the aim of this study is to assess the cytokine/chemokine network in individuals who have aMCI but do not have MDD, as well as the immune profiles of the qMCI and DSOA scores. The specific hypotheses aim to uncover the presence of immune activation in individuals with aMCI, as indicated by their immune profiles. Additionally, activated immune profiles, including the macrophage M1 profile, are expected to predict the qMCI and DSOA scores.

Participants

A cross-sectional study was conducted to compare individuals with aMCI to a group of healthy control subjects. The study sample comprised individuals of both genders, with an age range spanning from 60 to 75 years. The study recruited healthy participants from Bangkok, Thailand, whereas individuals with aMCI were recruited from the Outpatient Department of the Dementia Clinic at King Chulalongkorn Memorial Hospital in Bangkok, Thailand from May 2022 to March 2023. The clinical Petersen's criteria were utilized to diagnose aMCI in the older adult population. These criteria involve the identification of subjective and objective memory impairments, together with the lack of dementia and alterations in activities of daily living (ADL). Furthermore, people with amnestic mild cognitive impairment complied with the Petersen criteria and exhibited a modified Clinical Dementia Rating score of 0.5. The control group had a CDR score of 0 and did not meet Petersen's criteria [10]. The healthy older adults were recruited from the Health Check-up Clinic, members of neighbourhoods’ senior clubs, and the healthy, elderly carers of individuals with aMCI) who were patients at the Dementia Clinic, and senior volunteers affiliated with the Red Cross.

Participants with stroke, Parkinson's disease, any dementia subtype, multiple sclerosis, schizophrenia, bipolar disorder, autism, delirium, metabolic disorder, malaria, HIV, chronic obstructive pulmonary disease (COPD), chronic kidney disease, cancer, substance abuse, alcoholism, inability to speak or communicate, blindness or impaired vision even with corrective lenses, hearing loss, inability to sit stably due to physical conditions such as chronic pain or low back pain, and those who had undergone cognitive training within three months prior to the study were excluded from the study. Ultimately, the subjects were allocated to either of the two study groups, consisting of 60 individuals classified as healthy controls and 61 individuals diagnosed with aMCI.

Before taking part in the study, all controls and patients were required to submit written informed consent. The study conducted in this research adhered to ethical and privacy standards that are recognized both in Thailand and internationally. These standards are in accordance with the International Guideline for the Protection of Human Subjects, as mandated by influential documents such as the Declaration of Helsinki, the Belmont Report, the International Conference of Harmonization in Good Clinical Practice, and the CIOMS Guidelines. The present study received approval from the Institutional Review Board (IRB) of the Faculty of Medicine at Chulalongkorn University in Bangkok, Thailand (No. 0372/65).

Clinical assessments

We used a semi-structured interview to collect socio-demographic data comprising age, sex, relationship status, year of education, and marital status. The scales used to assess cognition were the Thai Mini-Mental State Examination (MMSE) [23], the Thai Montreal Cognitive Assessment (MoCA) [24], and three rating scales of the Thai Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Neuropsychological Assessment Battery [4]. The MMSE is a 30-question assessment of cognitive function [25]. The Thai version of the Mini-Mental State Examination was developed in 1993 and has been extensively used in Thailand to screen cognitive impairment and dementia [23]. The scale consists of six subtests measuring orientation, registration, attention, word recall, language, and computation. The total score ranges from 0 to 30. The MoCA was developed by Nasreddine et al. [26] as an effective and applicable screening tool for cognitive disorders. The Thai version of MoCA was used to screen and monitor cognitive impairments in the clinical practice of neurocognitive disorders validated in the Thai setting by Tangwongchai et al. [24]. This test measures various cognitive domains, namely: visuospatial/executive, naming, attention, language, abstraction, delayed recall, and orientation. The total sum of all individual scores (out of 30 maximum possible points) represents the severity of cognitive impairment. The qMCI score was derived as the first principal component derived from the MoCA, MMSE, and the CDR score [3].

To evaluate distress, depression, and anxiety symptoms, we utilized various assessment tools. These included the State-Trait Anxiety Inventory (STAI) developed by Spielberger et al. [27], the depression (HADS-D) and anxiety (HADS-A) subscales of the Thai version of Hospital Anxiety and Depression Scale developed by Nilchaikovit [28], the Perceived Stress Scale (PSS) by Wongpakaran, Wongpakaran [29], the neuroticism trait score from the Five Factor Model standardized psychometric pool of items (IPIP-NEO) by Yomaboot, Cooper [30], and the Thai Geriatric Depression Scale (TGDS) by Yesavage [31]. In a study conducted by [3], the DSOA dimension was constructed through PCA using the first PC extracted from STAI, HADS-D, HADS-A, PSS, STAI, TGDS, and the neuroticism score. To obtain a more homogeneous cohort of patients with aMCI, we have excluded subjects with DSOA symptoms (n = 9) as explained by [3]. This selected and homogeneous aMCI subset (n = 52) is known as mild cognitive dysfunction (mCoDy) to differentiate it from the broader MCI category [3].

Assays

To assay cytokines/chemokines we used fasting venous blood sampled between 7.00 a.m. and 9.00 a.m. We determined the concentrations of cytokines, chemokines, and growth factors in plasma samples using the 27-plex Bio-Plex Pro™ Human Chemokine Assays (Bio-Rad Laboratories, Inc. USA) as explained previously [32]. The LUMINEX 200 apparatus was used to measure the fluorescence intensities (FI), which are more suitable than absolute concentrations (particularly when multiple plates are utilized). Therefore, we used the blank subtracted FI values in our statistical analysis. It was determined that the intra-assay coefficient of variation values for each analyte were all below 11.0%. The concentrations were ascertained utilizing the standard concentrations supplied by the manufacturer. Following this, the proportion of concentrations surpassing the minimum measurable concentration (OOR) was computed. The analytes are detailed in Electronic Supplementary File (ESF), Table 1, along with the percentage of values that surpassed the OORs. Approximations of values below OOR values were achieved by utilizing the sensitivity of the assays. In the statistical analysis conducted on individual cytokines, chemokines, and growth factors, analytes whose concentrations were not detectable (< lower than the OOR) in over 50% of all assays were not entered as IF values but as prevalences (dummy variables: measurable versus non-measurable). However, in case less than 20% of the analytes were measurable, the variables were excluded from the analyses. Following this, IL-2, IL-5, IL-15, IL-17, and VEGF were excluded from the analysis. ESF, Table 2 lists the variables utilized in the construction of the subsequent immune profiles. Where needed, cytokines were used after logarithmic (log10), square root, fractional rank-based normal transformations, or Winsorization.

Table 1

Results of General Linear Model analyses that examine the association between immune-inflammatory biomarkers and the diagnosis of amnestic mild cognitive impairment (aMCI) versus healthy controls (HC), while adjusting for age, sex, and body mass index.
Tests	Dependent Variables	Explanatory variables	F	df	p	Partial Eta Squared
Univariate GLM	M1 Th1 Th2 IRS CIRS IRS/CIRS Chemokine T cell growth PC_Immune	aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC	3.246 9.818 2.144 9.815 2.372 5.079 1.455 10.493 8.236	1/119 1/119 1/119 1/119 1/119 1/119 1/119 1/119 1/119	0.074 0.002 0.146 0.002 0.126 0.026 0.230 0.002 0.005	0.027 0.076 0.018 0.076 0.020 0.041 0.012 0.081 0.065
Significant Univariate GLM	IL1β IL6 IL7 IL12p70 IL13 GM-CSF MCP-1	aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC aMCI/HC	13.902 4.371 7.941 10.685 4.534 7.830 6.626	1/119 1/119 1/119 1/119 1/119 1/119 1/119	< 0.001 0.039 0.006 0.001 0.035 0.006 0.011	0.105 0.035 0.063 0.082 0.037 0.062 0.053

Table 2

Results of multivariate General Linear Model analyses which examine the associations between the Neurotoxic and Neuroprotective immune indices and their ratio and the diagnosis of amnestic mild cognitive impairment (aMCI) versus healthy controls (HC).
Variables	HC (n = 60)	aMCI (n = 61)	F	df	p
Neurotoxic (3NT) index	-0.030 (0.130)	0.030 (0.129)	0.107	1/119	0.744
Neuroprotective (7NP) index	0.342 (0.122)	-0.337 (0.121)	15.636	1/119	< 0.001
3NT/7NP	-0.364 (0.121)	0.358 (0.120)	18.005	1/119	< 0.001

Data analysis

Differences in continuous variables between groups were checked using analysis of variance (ANOVA). Analysis of contingency tables (the χ2-test) was used to determine the association between nominal variables. Correlations between two variables were assessed using Pearson’s product-moment correlation coefficients. Multivariate and univariate general linear model (GLM) analysis was used to examine the relationships between diagnostic classifications and clinical and cognitive data after covarying for gender, age, and body mass index. Subsequently, the estimated marginal means (SE) were computed from the GLM model after adjusting for the gender, age, and body mass index variables. We performed multiple regression analysis (manual and automatic stepwise) to determine which test scores best predicted the clinical scores and to compute and display partial regression analysis. For this analysis, we always confirmed multivariate normality, homoscedasticity, and the absence of collinearity and multicollinearity. The study employed manual and automatic stepwise binary logistic regression analysis to evaluate the explanatory variables that significantly predicted the diagnosis of aMCI or mCoDy as the dependent variable. The control group served as the reference group. Odds ratios were calculated with 95% confidence intervals (CI), and Nagelkerke values were utilized to estimate the effect size. The regression analyses’ results were always bootstrapped using 1,000 bootstrap samples, and the latter were reported if the findings were not concordant. Statistical tests were two-tailed and a p-value of 0.05 was used for statistical significance. IBM SPSS Windows version 29 was used for all statistical analyses.

Socio-demographic and clinical Data

ESF, Table 3 displays the demographics and clinical features of the two research groups. The cognitive assessments demonstrated significant differences among the groups with lower MMSE and MoCA scores in aMCI than in controls. There was a trend towards increased qMCI and DSOA scores in aMCI. Certain participants received treatment consisting of oral antidiabetica (6 controls and 10 aMCI, X² = 1.08, df = 1, p = 0.299), antihypertensive drugs (17 controls and 26 aMCI, X² = 2.70, df = 1, p = 0.101), and lipid-lowering drugs (36 controls and 36 aMCI, X² = 0.12, df = 1, p = 0.912). Several of the participants consumed vitamin (A, B, C, D, E) preparations (34 controls and 30 aMCI, X² = 0.68, df = 1, p = 0.409), fish oil (5 controls and 10 aMCI, X² = 1.81, df = 1, p = 0.179), or folic acid (3 controls and 2 aMCI, Fisher's exact probability test: p = 0.680). However, no statistically significant correlations were observed between any of these medications and the immune profiles. Furthermore, the inclusion of these drug state variables as covariates in the GLM analyses had no impact on the outcomes detailed below. Consequently, the patients' medication status had no bearing on the findings of this research.

Table 3

Results of binary logistic regression with diagnosis as dependent variable and the immune biomarkers and solitary cytokines and chemokines as explanatory variables.
Dependent variables	Explanatory variable	B	S.E.	W	P	OR	95% CI	Omnibus model X²	df	p	Nagelkerke pseudo-R2
Model 1								40.745	3	< 0.001	0.381
	Education	-0.245	0.07	12.21	< 0.001	0.783	0.683–0.898
	7NP	-1.682	0.398	17.845	< 0.001	0.186	0.085–0.406
	3NT	0.386	0.12	10.43	0.001	1.472	1.164–1.861
Model 2								64.507	5	< 0.001	0.551
	Education	-0.237	0.074	10.356	0.001	0.789	0.683–0.911
	IL1β	-1.065	0.271	15.393	< 0.001	0.345	0.203–0.587
	IL7	-1.257	0.315	15.913	< 0.001	0.284	0.153–0.528
	MCP-1	-1.067	0.302	12.518	< 0.001	0.344	0.190–0.621
	CCL5	1.084	0.335	10.448	0.001	2.956	1.532–5.702
Model 3								44.500	3	< 0.001	0.447
	Education	-0.35	0.086	16.492	< 0.001	0.705	0.595–0.834
	7NP	1.045	0.304	11.795	0.001	2.843	1.566–5.161
	3NT	-1.562	0.407	14.7	< 0.001	0.21	0.094–0.466

Differences in immune-inflammatory biomarkers scores between the diagnostic groups

Table 1 indicates that there are significant associations between the diagnosis (aMCI/HC) and immune-inflammatory biomarkers after controlling for age, sex, and BMI. Sex (p = 0.714), age (p = 0.963), and BMI (p = 0.0103) did not have any significant effect in the multivariate GLM analysis, whereas diagnosis yielded a significant effect (F = 2.00, df = 9/108, p = 0.046, partial eta squared = 0.143). Univariate GLM showed significant differences in Th1, IRS, IRS/CIRS, T cell growth and PC_Immune profiles between patients with aMCI and controls. All differences remained significant after FDR p correction (at p = 0.0468). The estimated marginal mean values of the biomarkers acquired from the GLM analysis, as demonstrated in Table 1, are presented in ESF, Table 4. Healthy controls had higher levels of M1, Th1, Th2, IRS, CIRS, IRS/CIRS, Chemokine, T cell growth, and PC_Immune scores compared to subjects with aMCI.

Table 4

Correlation matrix between clinical and neuropsychiatric scores with the measured immune markers.
	qMCI	DSOA	MoCA	MMSE
qMCI	1	0.138	-0.901^**	-0.860^**
DSOA	0.138	1	-0.165	-0.060
MoCA	-0.901^**	-0.165	1	0.561^**
MMSE	-0.860^**	-0.060	0.561^**	1
3NT	0.062	0.121	-0.051	-0.063
7NP	-0.232^*	-0.056	0.216^*	0.156
3NT/7NP	0.287^**	0.172	-0.261^**	-0.214^*
IL1β	-0.224^*	-0.004	0.250^**	0.093
IL6	-0.327^**	0.060	0.257^**	0.299^**
IL7	-0.249^**	-0.098	0.249^**	0.154
IL12p70	-0.242^**	-0.146	0.244^**	0.147
IL13	-0.253^**	-0.052	0.198^*	0.246^**
GM-CSF	-0.250^**	-0.042	0.273^**	0.137
MCP-1	-0.289^**	-0.027	0.239^**	0.252^**

Since the primary analysis on the immune profiles yielded significant results, we have examined the differences in the separate cytokines, chemokines, and growth factors between the study groups. The aMCI group had lower levels of IL1β, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1 in comparison to controls (see Table 1 and ESF, Table 4). As reviewed in the Discussion, these 7 cytokines/chemokines show, at physiologic levels, neuroprotective effects. Consequently, we have computed a z unit-based composite as IL1β (z IL1β) + z IL6 + z IL7 + z IL12p70 + z IL13 + z GM-CSF + z MCP1, labelled neuroprotective index or 7NP.

Consequently, we have also computed the differences between the mCoDy group and controls as shown in ESF, Tables 5 and ESF, Table 6. The healthy control group exhibited higher mean values for the Th1, IRS, T cell growth, and PC_Immune profiles, in comparison to the mCoDy group. The series mean values of various pro-inflammatory cytokines, including IL1β, IL6, IL7, IL12p70, GM-CSF, and MCP-1, were found to be greater in the healthy control group compared to the mCoDy group.

Table 5

Results of multiple regression analyses with quantitative Mild Cognitive Impairment (qMCI) scores as dependent variables.
Dependent variables	Explanatory variable	Coefficients of input variables			Model statistics
Dependent variables	Explanatory variable	β	t	p	F	df	p	R²
#1. qMCI	Model				14.163	4/116	< 0.001	0.328
	Education	-0.366	-4.571	< 0.001
	3NT	0.585	4.820	< 0.001
	PC_Immune	-0.582	-4.809	< 0.001
	Age	0.175	2.187	0.031
#2. qMCI	Model				11.753	6/114	< 0.001	0.382
	Education	-0.392	-5.260	< 0.001
	MCP-1	-0.309	-3.719	< 0.001
	IL13	-0.201	-2.553	0.012
	CCL5	0.338	3.913	< 0.001
	IL7	-0.226	-2.759	0.007
	IL1β	-0.149	-1.995	0.048
#3. DSOA	Model				1.622	1.816	0.148	0.045
	Education	0.120	1.302	0.196
	3NT	0.169	1.611	0.110
	NP	-0.134	-1.286	0.201

Differences in neurotoxicity and neuroprotection scores between the diagnostic groups

Our results of multivariable regression analyses showed that 3 chemokines frequently appeared as explanatory variables after considering the effects of the 7NP index, namely CXCL8, CCL5, and CCL11. Consequently, we have computed an index of neurotoxic chemokines as z CXCL8 + z CCL11 + z CCL5, denoted as neurotoxic (3NT) index (the Discussion reviews their NT potential). Consequently, we computed the z 3NT – z 7NP composite (labeled 3NT/7NP). Table 2 shows the mean values of 3NT, 7NP, and 3NT/7NP in aMCI and control subjects. There was no statistically significant difference in 3NT between aMCI and controls, whereas 7NP was significantly lowered in aMCI as compared with controls.

Prediction of aMCI using immune markers

Table 3 presents the results of a binary logistic regression analysis conducted to investigate whether immune markers predict aMCI and mCoDy versus controls. The dependent variable in this analysis was the presence of aMCI or mCoDy with controls as the reference group. The results of Model 1 demonstrated that education years, 7NP (both inversely), and 3NT (positively) had a substantial impact on the probability of developing aMCI (effect size of 0.381). Model 2 used the separate cytokines/chemokines in the same framework. The effect size of this model was shown to be higher (Nagelkerke increased to 0.551). The best predictors of aMCI were IL7, IL1β, MCP-1, CCL5, and education. Removing CCL5 showed that CXCL8 became a significant predictor (p = 0.005). In Model 3, the restricted mCoDy group was utilized as dependent variable (and controls as reference group). The model showed a better fit comparable to Model 1 in terms of its effect size (Nagelkerke pseudo-R² = 0.447), while using the same predictors.

Correlation matrix between cognitive test results and immune profiles

As presented in Table 4, the qMCI score showed significant and inverse associations with 7NP, IL1β, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1, and a positive correlation with the 3NT/7NP ratio. The same variables were also associated with the MoCA score (but all in the opposite direction as compared with the qMCI score). The MMSE score was significantly associated with the 3NT/7NA ratio (inversely), IL6, IL13, and MCP-1 (all positively). The study findings indicate that there is no significant correlation between DSOA scores and any of the cognitive tests and immune markers.

Prediction of the qMCI and DSOA scores using immune markers

Table 5 shows the outcome of regression analyses with the qMCI and DSOA scores as dependent variables and either the immune profiles or the separate cytokine/chemokines as explanatory variables. Model 1 shows that education, 3NT, PC_Immune, and age largely predict the qMCI score (32.8% of the variance). Thus, lowered immune functions, higher neurotoxicity and age, and lower education were associated with higher qMCI scores. Model 2 shows that CCL5 (positively) and education, MCP-1, IL13, IL7, and IL-1β (all inversely) were significantly associated with qMCI and explained 38.2% of its variance. Model 3 shows that 3NT and 7NP did not predict the DSOA score. In addition, after using all immune profiles or cytokines/chemokines/growth factors as explanatory variables, it was found that none of the immune variables or any of their combinations could explain the DSOA score.

Immune-inflammatory biomarkers in aMCI

The first major finding of our study is the notable assocation between the diagnosis of aMCI and immune-inflammatory profiles. Notably, there were significant reductions in Th1, IRS, IRS/CIRS, T cell growth, and PC_immune profiles in individuals with aMCI compared to healthy controls. Our findings indicate that aMCI is distinguished by a suppression of specific immune functions and a general immunosuppression, rather than immune activation or inflammation. Furthermore, significant reductions were observed in IL1β, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1 levels in individuals with aMCI compared to the control group.

Therefore, these results contradict previous findings in MCI. As previously discussed in the Introduction, several studies have reported elevated levels of inflammatory or immune markers in individuals with MCI [14, 16, 17, 33]. In the current study, it was found that two out of the three cytokines/chemokines analyzed by Shen et al. [17] showed a decrease rather than an increase. Specifically, IL6 and MCP-1 exhibited a decrease in their levels in aMCI. As such, our results agree with those of a previous meta-analysis which found no significant variations in immune markers between individuals with MCI and control subjects [18].

One of the main reasons for these variations is that our study was conducted on a highly selected and well-phenotyped group of individuals with aMCI or mCoDy, who were meticulously chosen to exclude those with MDD and DSOA symptoms. Including MDD patients in the aMCI study group can introduce bias due to the characteristic increase in M1, Th1, IRS, T cell growth, and chemokine profiles observed in MDD [21]. In addition, the current study took into account BMI, age, and sex when analyzing the data. These factors can potentially introduce bias in immune variables.

Lowered levels of neuroprotective cytokines/chemokines in aMCI

It is worth mentioning that the cytokines/chemokines that are downregulated in aMCI have pro-inflammatory effects when increased, as observed in MDD [21]. However, it should be stressed that the 7 cytokines/chemokines that exhibit a decrease in aMCI have been found to have neuroprotective effects at normal levels. These include IL1β, IL6, IL7, IL12p70, IL13, GM-CSF, and MCP-1. As an illustration, there is empirical evidence suggesting that IL1β, at normal physiological levels, may play a role in maintaining the health and functioning of neurons [34, 35]. In a recent study conducted by Alsbrook et al. [34], it was found that IL1β plays a crucial role in the intricate processes of tissue healing and neuroplasticity. Excessive levels of IL6 are usually linked to negative effects that can lead to cognitive impairment [36]. However, maintaining normal levels of IL6 seems to be crucial for preserving different aspects of neuronal health [36, 37]. Research has shown that IL7 plays a crucial role in maintaining glucose homeostasis and has the potential to aid in neurorecovery following brain damage [38]. IL12p70 plays a crucial role in preserving neuronal health by regulating the inflammatory conditions in the central nervous system [39]. In a recent study by Huan et al. [40], it was found that IL12p70 plays a crucial role in promoting neurogenesis, synaptic plasticity, regulating neurotrophic factors, and ensuring the survival of neurons. In a recent study conducted by Yang et al. [41], it was discovered that individuals with higher levels of IL12p70 experience a decelerated cognitive decline. Additionally, these individuals also exhibited reduced tau levels and a decrease in neurodegeneration, particularly among those with elevated amyloid beta. IL13 has been found to play a role in reducing neuroinflammation by promoting the M2 microglia phenotype and contributing to the death of the microglia M1 phenotype, as demonstrated in studies by Mori et al. [42] and Miao et al. [43]. In addition, IL13 has been shown to enhance functional recovery following traumatic brain injury through its anti-inflammatory and neuroprotective properties [43]. GM-CSF has the ability to regulate the activities of microglia, which can potentially improve the survival of neurons [44]. This suggests that GM-CSF plays a role in maintaining the health of neurons when present at normal concentrations [44]. In addition, this factor activates mesenchymal stem cells (MSCs) found in the bone marrow. MSCs have been studied for their positive impact on cognition and regeneration, particularly in relation to Alzheimer’s disease [45, 46] and impaired neurocognitive functions [47]. The potential role of MCP-1 in mediating the neuroprotective effects of noradrenaline and its ability to prevent ATP loss has been suggested by Madrigal et al. [48].

The reduced levels of these cytokines and the general suppression of the immune system suggest that aMCI and mCoDy are not caused by heightened immune activation or inflammation. Our results suggest that the protective functions of these cytokines/chemokines, which are typically achieved at normal levels, may be weakened in subjects with aMCI, potentially leading to reduced neuroprotection.

Neurotoxic cytokines/chemokines in aMCI and mCoDy

It is worth noting that our multivariate regression analyses revealed an intriguing finding. Upon incorporating the aforementioned neuroprotective immune compounds, three neurotoxic chemokines, specifically CCL11, CCL5, and CXCL8, emerged as significant predictors in the final regression model. By analyzing a combination of these three chemokines, we were able to create a composite score. This score allowed us to determine that a decrease in the neuroprotective index, along with an increase in this neurotoxicity index, strongly predicted aMCI or mCoDy as compared to controls. CCL5 (or RANTES) has been associated with a wide variety of neurodegenerative diseases [49]. CCL11 plays a significant role in elucidating the cognitive impairments associated with depression and major psychoses. It disrupts neurogenesis and the functions of the BBB, as reviewed by Ivanovska et al. [50]. CXCL8 plays a crucial role in the intricate web of inflammation and may be linked to cognitive impairment and various mental health conditions [51].

On the other hand, other neurotoxic cytokines such as IL15 and IL17 were not even measurable in the current study group. According to a study conducted by Di Castro et al. [52], IL15, a proinflammatory cytokine, has been found to have a negative impact on episodic memory. IL17 plays a significant role in promoting inflammation, disrupting the blood-brain barrier (BBB), and causing tissue damage in conditions such as Alzheimer’s disease [53]. Research has shown that IL17 has been linked to negative effects on neuronal functions and overall brain health [54]. Nevertheless, these cytokines, which play a role in MDD [21], are not involved in the pathophysiology of aMCI.

Prediction of the quantitative qMCI and DSOA scores.

One notable discovery from this study is the significant correlation between the qMCI score and indicators of immunosuppression and increased neurotoxicity (after considering the effects of confounders such as age and education). These factors, when considered together, accounted for 32.8% of the variance in qMCI. This suggests that aMCI may be influenced by reduced neuroprotection and weakened immune defenses, as indicated by lower levels of certain cytokines and chemokines. The decreased levels of these compounds in aMCI may result in reduced neuroprotection, potentially rendering these individuals more vulnerable to the effects of neurotoxic chemokines. This combination could ultimately lead to neuronal damage and cognitive decline. Therefore, it appears that the delicate interplay between neurotoxic and neuroprotective factors may play a crucial role in the advancement of cognitive decline.

This condition exhibits similarities to recent discoveries in schizophrenia, where a decline in overall cognitive abilities, including executive functions, attention, semantic and episodic memory, is linked to an elevated ratio of immune-linked neurotoxicity to neuroprotection [55–57]. However, it is worth noting that the neurotoxicity index shows a significant increase in schizophrenia, which helps to explain why the neurocognitive disorders in deficit schizophrenia are more pronounced compared to aMCI [58].

Nevertheless, the study findings suggest that there are no significant associations between the DSOA symptoms and the immune markers that were examined. In a previous study, it was discovered that a significant portion of the variation in the DSOA score could be attributed to psychosocial stressors, specifically negative life events and adverse childhood experiences [3]. It appears that DSOA, as opposed to the more severe depressive symptoms of MDD, is characterized by a psychological state in which negative cognitions dominate. On the other hand, in MDD, the heightened neurotoxicity associated with the immune system is influenced, to some extent, by negative experiences during childhood and adverse events in life [59].

Our thorough investigation provides insight into the various dynamics of aMCI, highlighting the significant impact of immunosuppression and reduced neuroprotection, as well as the elevated neurotoxicity of CCL11, CCL5, and CXCL8. The findings emphasize the importance of maintaining a delicate balance between neurotoxicity and neuroprotection during the progression of aMCI. Immunosuppression seems to be the main factor contributing to aMCI, rather than immune activation. It is possible to consider that the decline in immune function and reduced neuroprotection could be a contributing factor in the progression from mild cognitive impairment to Alzheimer's disease. Our findings deserve replication in other countries and ethnicities. If replicated, the immunosuppression of neuroprotective cytokines/chemokines may be a new drug target to treat aMCI. Future research on aMCI should always consider MDD and the possible intervening effects of DSOA symptoms.

Availability of data and materials: The dataset generated during and/or analysed during the current study will be available from MM upon reasonable request and once the authors have fully exploited the dataset.

Author’s contributions: All authors contributed to the paper. MM, CT, and V-LT-C: conceptualization and study design. V-LT-C and MM: first draft writing. V-LT-C, MM, CT, SH, GN, DS, KS, and MS: editing. GN, CT, and V-LT-C: recruitment of patients. MM and V-LT-C: Statistical analyses. All authors revised and approved the final draft.

Financial support: This research is supported by the Ratchadapisek Sompoch Fund, Faculty of Medicine, Chulalongkorn University (Grant no. GA66/037); and the 90th Anniversary of Chulalongkorn University Scholarship under the Ratchadapisek Somphot Endowment Fund (Grant no. GCUGR1125661006D), Thailand. MM received funding from the Thailand Science Research and Innovation Fund, Chulalongkorn University (HEA663000016), and a Sompoch Endowment Fund (Faculty of Medicine), MDCU (RA66/016).

Competing interest: MS received honoraria and has been a consultant for AbbVie, Angelini, Lundbeck, Otsuka. Other authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported.

Institutional Review Board Statement: This study was approved by the Institutional Review Board (IRB) of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (IRB no. 0372/65), which complies with the International Guideline for Human Research Protection as required by the Declaration of Helsinki.

Informed consent: Before taking part in the study, all participants and/or their caregivers provided written informed consent.

Anderson ND. State of the science on mild cognitive impairment (MCI). CNS Spectrums. 2019;24(1):78–87. doi: 10.1017/S1092852918001347.
Nantachai G, Maes M, Tran-Chi V-L, Hemrungrojn S, Tunvirachaisakul C. Neurocognitive features of mild cognitive impairment and distress symptoms in older adults without major depression. medRxiv2023. p. 1–27.
Tran-Chi V-L, Maes M, Nantachai G, Hemrungrojn S, Solmi M, Tunvirachaisakul C. Distress Symptoms of Old Age and Mild Cognitive Impairment are Two Distinct Dimensions in Older Adults Without Major Depression. Psychology Research and Behavior Management. 2024:101 – 16. doi: 10.2147/PRBM.S447774.
Tunvirachaisakul C, Supasitthumrong T, Tangwongchai S, Hemrunroj S, Chuchuen P, Tawankanjanachot I, et al. Characteristics of mild cognitive impairment using the Thai version of the consortium to establish a registry for Alzheimer’s disease tests: a multivariate and machine learning study. Dementia and Geriatric Cognitive Disorders. 2018;45(1):38–48. doi: 10.1159/000487232.
Dwolatzky T, Whitehead V, Doniger GM, Simon ES, Schweiger A, Jaffe D, et al. Validity of the Mindstreams™ computerized cognitive battery for mild cognitive impairment. Journal of Molecular Neuroscience. 2004;24:33–44. doi: 10.1385/JMN:24:1:033.
Gualtieri CT, Johnson LG. Neurocognitive testing supports a broader concept of mild cognitive impairment. Am J Alzheimers Dis Other Demen. 2005;20(6):359–66. doi: 10.1177/153331750502000607.
Hemrungrojn S, Tangwongchai S, Charoenboon T, Panasawat M, Supasitthumrong T, Chaipresertsud P, et al. Use of the Montreal Cognitive Assessment Thai Version to Discriminate Amnestic Mild Cognitive Impairment from Alzheimer's Disease and Healthy Controls: Machine Learning Results. Dementia and Geriatric Cognitive Disorders. 2021;50(2):183–94. doi: 10.1159/000517822.
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201–9. doi: 10.1212/WNL.0b013e3181cb3e25.
Maes M, Tangwongchai S. Mild cognitive impairment vs. mild cognitive dysfunctions: validation with a nomothetic network approach. Ageing and Neurodegenerative Diseases. 2021;1(5):1–15. doi: 10.20517/and.2021.08.
Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 2004;256(3):183–94. doi: 10.1111/j.1365-2796.2004.01388.x.
Maes M, DeVos N, Wauters A, Demedts P, Maurits V, Neels H, et al. Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer’s disease. Journal of Psychiatric Research. 1999;33(5):397–405. doi: 10.1016/S0022-3956(99)00016-3.
Xie J, Van Hoecke L, Vandenbroucke RE. The impact of systemic inflammation on Alzheimer’s disease pathology. Frontiers in Immunology. 2022;12:1–18. doi: 10.3389/fimmu.2021.796867.
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2018;4:575–90. doi: 10.1016/j.trci.2018.06.014.
Schmidt-Morgenroth I, Michaud P, Gasparini F, Avrameas A. Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;24(13):1–19. doi: 10.3390/ijms241310523.
Zheng M, Chang B, Tian L, Shan C, Chen H, Gao Y, et al. Relationship between inflammatory markers and mild cognitive impairment in Chinese patients with type 2 diabetes: a case-control study. BMC Endocrine Disorders. 2019;19:1–10. doi: 10.1186/s12902-019-0402-3.
Contreras JA, Aslanyan V, Albrecht DS, Mack WJ, Initiative AsDN, Pa J. Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2022;14(1):1–10. doi: 10.1002/dad2.12346.
Shen X-N, Niu L-D, Wang Y-J, Cao X-P, Liu Q, Tan L, et al. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. Journal of Neurology, Neurosurgery & Psychiatry. 2018;90(5):590–8. doi: 10.1136/jnnp-2018-319148.
Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctot KL. Inflammatory markers in mild cognitive impairment: a meta-analysis. Journal of Alzheimer's Disease. 2015;47(3):669–79. doi: 10.3233/JAD-150042.
Maes M, Bosmans E, Suy E, Vandervorst C, De Jonckheere C, Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 1990;24(3):115–20. doi: 10.1159/000119472.
Maes M, Scharpé S, Meltzer HY, Bosmans E, Suy E, Calabrese J, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Research. 1993;49(1):11–27. doi: 10.1016/0165-1781(93)90027-E.
Maes M, Carvalho AF. The compensatory immune-regulatory reflex system (CIRS) in depression and bipolar disorder. Molecular Neurobiology. 2018;55:8885–903. doi: 10.1007/s12035-018-1016-x.
Maes M, Jirakran K, Vasupanrajit A, Zhou B, Tunvirachaisakul C, Almulla AF. Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are all associated with neurotoxic immune networks and their intricate interactions with metabolic syndrome. medRxiv2023. p. 1–42.
Train the Brain Forum Committee. Thai Mental State Examination (TMSE). Siriraj Hosp Gaz. 1993;45:661–74.
Tangwongchai S, Phanasathit M, Charernboon T, Akkayagorn L, Hemrungrojn S, Phanthumchinda K, et al. The validity of Thai version of the Montreal Cognitive Assessment (MoCA-T). Dement Neuropsychol. 2009;3(2):172.
Folstein, Folstein, McHugh. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–98. doi: 10.1016/0022-3956(75)90026-6.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005;53(4):695–9. doi: 10.1111/j.1532-5415.2005.53221.x.
Spielberger CD, Gonzalez-Reigosa F, Martinez-Urrutia A, Natalicio LF, Natalicio DS. The state-trait anxiety inventory. Revista Interamericana De Psicología/Interamerican Journal of Psychology. 1971;5(3 & 4):145–58. doi: 10.30849/rip/ijp.v5i3%20&%204.620.
Nilchaikovit T. Development of Thai version of hospital anxiety and depression scale in cancer patients. Journal of the Psychiatrist Association of Thailand. 1996;41(1):18–30.
Wongpakaran N, Wongpakaran T. The Thai version of the PSS-10: An Investigation of its psychometric properties. BioPsychoSocial medicine. 2010;4:1–6. doi: 10.1186/1751-0759-4-6.
Yomaboot P, Cooper AJ. Factor structure and psychometric properties of the International Personality Item Pool-NEO (IPIP-NEO) Thai version. Journal of Somdet Chaopraya Institute of Psychiatry. 2016;10(2):36–49.
Yesavage JA. Imagery pretraining and memory training in the elderly. Gerontology. 1983;29(4):271–5. doi: 10.1159/000213126.
Maes M, Abe Y, Sirichokchatchawan W, Suwimonteerabutr J, Sangkomkamhangd U, Almulla AF, et al. The cytokine, chemokine, and growth factor network of prenatal depression. Brain Sciences. 2023;13(5):727. doi: 10.3390/brainsci13050727.
Zheng M, Chang B, Tian L, Shan C, Chen H, Gao Y, et al. Relationship between inflammatory markers and mild cognitive impairment in Chinese patients with type 2 diabetes: a case-control study. BMC Endocr Disord. 2019;19(1):73. doi: 10.1186/s12902-019-0402-3.
Alsbrook DL, Di Napoli M, Bhatia K, Biller J, Andalib S, Hinduja A, et al. Neuroinflammation in acute ischemic and hemorrhagic stroke. Current Neurology and Neuroscience Reports. 2023;23(8):407–31. doi: 10.1007/s11910-023-01282-2.
Poh L, Sim WL, Jo DG, Dinh QN, Drummond GR, Sobey CG, et al. The role of inflammasomes in vascular cognitive impairment. Mol Neurodegener. 2022;17(1):4. doi: 10.1186/s13024-021-00506-8.
Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opinion on Therapeutic Targets. 2014;18(5):495–512. doi: 10.1517/14728222.2014.888417.
Chae J-w, Ng T, Yeo HL, Shwe M, Gan YX, Ho HK, et al. Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. PLOS ONE. 2016;11(10):e0164204. doi: 10.1371/journal.pone.0164204.
Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood, The Journal of the American Society of Hematology. 2008;111(4):2101–11. doi: 10.1182/blood-2007-06-096297.
Verma ND, Hall BM, Plain KM, Robinson CM, Boyd R, Tran GT, et al. Interleukin-12 (IL-12p70) promotes induction of highly potent Th1-like CD4 + CD25 + T regulatory cells that inhibit allograft rejection in unmodified recipients. Frontiers in Immunology. 2014;5:1–11. doi: 10.3389/fimmu.2014.00190.
Huan X, Zhao R, Song J, Zhong H, Su M, Yan C, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunology. 2022;23(1):26. doi: 10.1186/s12865-022-00501-8.
Yang H-S, Zhang C, Carlyle BC, Zhen SY, Trombetta BA, Schultz AP, et al. Plasma IL-12/IFN-γ axis predicts cognitive trajectories in cognitively unimpaired older adults. Alzheimer's & Dementia. 2022;18(4):645–53. doi: 10.1002/alz.12399.
Mori S, Maher P, Conti B. Neuroimmunology of the Interleukins 13 and 4. Brain Sciences. 2016;6(2):18. doi: 10.3390/brainsci6020018.
Miao W, Zhao Y, Huang Y, Chen D, Luo C, Su W, et al. IL-13 Ameliorates Neuroinflammation and Promotes Functional Recovery after Traumatic Brain Injury. The Journal of Immunology. 2020;204(6):1486–98. doi: 10.4049/jimmunol.1900909.
Dikmen HO, Hemmerich M, Lewen A, Hollnagel J-O, Chausse B, Kann O. GM-CSF induces noninflammatory proliferation of microglia and disturbs electrical neuronal network rhythms in situ. Journal of Neuroinflammation. 2020;17(1):235. doi: 10.1186/s12974-020-01903-4.
Hernández A, García E. Mesenchymal stem cell therapy for Alzheimer’s disease. Stem Cells International. 2021;2021:7834421. doi: 10.1155/2021/7834421.
Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1–42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Human Molecular Genetics. 2009;18(20):3876–93. doi: 10.1093/hmg/ddp331.
Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Suzuki J, Sasaki Y, et al. Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model. Neuroscience. 2019;408:361–77. doi: 10.1016/j.neuroscience.2019.04.018.
Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. Journal of Neuroscience. 2009;29(1):263–7. doi: 10.1523/JNEUROSCI.4926-08.2009.
Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective role. Neurobiology of Aging. 2010;31(1):8–16. doi: 10.1016/j.neurobiolaging.2008.03.009.
Ivanovska M, Abdi Z, Murdjeva M, Macedo D, Maes A, Maes M. CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals. 2020;13(9):230. doi: 10.3390/ph13090230.
Tsai S-J. Role of interleukin 8 in depression and other psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021;106:110173. doi: 10.1016/j.pnpbp.2020.110173.
Di Castro MA, Garofalo S, Mormino A, Carbonari L, Di Pietro E, De Felice E, et al. Interleukin-15 alters hippocampal synaptic transmission and impairs episodic memory formation in mice. Brain, Behavior, and Immunity. 2024;115:652–66. doi: 10.1016/j.bbi.2023.11.015.
Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, et al. Interleukin-17 in chronic inflammatory neurological diseases. Frontiers in immunology. 2020;11:1–15. doi: 10.3389/fimmu.2020.00947.
Lu Y, Zhang P, Xu F, Zheng Y, Zhao H. Advances in the study of IL-17 in neurological diseases and mental disorders. Frontiers in Neurology. 2023;14:1–16. doi: 10.3389/fneur.2023.1284304.
Maes M. Major neurocognitive psychosis: A novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin’s and Bleuler’s conceptions. Acta Neuropsychiatrica. 2023;35(3):123–37. doi: 10.1017/neu.2022.32.
Maes M. The Gold Standard Diagnosis of Schizophrenia is Counterproductive: Towards Quantitative Research and Diagnostic Algorithmic Rules (RADAR) and their Derived Qualitative Distinct Classes. Current Topics in Medicinal Chemistry. 2024;24(28):1–36. doi: 10.2174/0115680266295129240415120646.
Maes M, Vojdani A, Sirivichayakul S, Barbosa DS, Kanchanatawan B. In schizophrenia, chronic fatigue syndrome-and fibromyalgia-like symptoms are driven by breakdown of the paracellular pathway with increased zonulin and immune activation-associated neurotoxicity. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2023;22(2):215–25. doi: 10.2174/1871527321666220806100600.
Kanchanatawan B, Tangwongchai S, Supasitthumrong T, Sriswasdi S, Maes M. Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnestic mild cognitive impairment. PLoS One. 2018;13(5):1–21. doi: 10.1371/journal.pone.0197004.
Almulla AF, Algon AAA, Maes M. Adverse childhood experiences and recent negative events are associated with activated immune and growth factor pathways, the phenome of first episode major depression and suicidal behaviors. Psychiatry Research. 2024;334:1–11. doi: 10.1016/j.psychres.2024.115812.

No competing interests reported.

ELECTRONICSUPPLEMENTARYFILE162024.docx

Download PDF

Editorial decision: Revision requested
12 Aug, 2024
Reviews received at journal
08 Aug, 2024
Reviewers agreed at journal
30 Jul, 2024
Reviews received at journal
27 Jul, 2024
Reviewers agreed at journal
15 Jul, 2024
Reviewers invited by journal
15 Jul, 2024
Editor assigned by journal
15 Jul, 2024
Editor invited by journal
11 Jul, 2024
Submission checks completed at journal
10 Jul, 2024
First submitted to journal
09 Jul, 2024

You are reading this latest preprint version

Is Amnestic Mild Cognitive Impairment a Neuro-Immune Condition?

Status:

Version 1

Abstract

Objectives

Design:

Setting:

Participants

Measurements

Results

Discussion

Introduction

Materials and Methods

Participants

Clinical assessments

Assays

Data analysis

Results

Socio-demographic and clinical Data

Differences in immune-inflammatory biomarkers scores between the diagnostic groups

Differences in neurotoxicity and neuroprotection scores between the diagnostic groups

Prediction of aMCI using immune markers

Correlation matrix between cognitive test results and immune profiles

Prediction of the qMCI and DSOA scores using immune markers

Discussion

Immune-inflammatory biomarkers in aMCI

Lowered levels of neuroprotective cytokines/chemokines in aMCI

Neurotoxic cytokines/chemokines in aMCI and mCoDy

Conclusion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1